Matritech, Sysmex end partnership:
This article was originally published in Clinica
Executive Summary
Diagnostics specialist Matritech has regained full rights to its NMP 179 cervical cancer technology, after terminating a worldwide license agreement with its development partner Sysmex. The companies will end their collaboration, initiated in 2002 (see Clinica No 1035, p 14), to develop an automated process of screening cervical cell specimens that would combine Matritech's patented biomarker with Sysmex' flow cytometry know-how. The move comes after Newton, Massachusetts-based Matritech agreed to be acquired by Inverness Medical Innovations in August (see Clinica No 1271, p 3). The use of NMP179 protein biomarker in Pap tests could help increase the accuracy of visually identifying cervical cells which need inspection by pathologists, according to the company.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.